SYDNEY, AUSTRALIA – 22 March 2019 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 10,232,038) entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response” by the United States Patent Office.
This United States patent was filed as a continuation application, and follows the grant of the United States by the United States parent patent which was issued in February 2017, as announced to the market.
For further information please download PDF attached:
Download this document
